Cue Biopharma CUE 深 滬
等待開盤 09-25 09:30:00 美东时间
32.85
+1.140
+3.60%
華盛通- 最 高33.635
- 今 開31.15
- 成交量 32.80万股
- 最 低 30.435
- 昨 收 31.71
- 總市值 2.39亿
- 52周最高 45.50
- 市盈率 靜 --
- 換手率 4.52%
- 52周最低 4.971
- 委 比 -85.29%
- 總股本 726.44万
- 歷史最高 950.70
- 量 比 0.27
- 振 幅 10.09%
- 歷史最低 4.971
- 每 手 1
- 風險率 8.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多What's Going on With Cue Biopharma Stock on Monday?
Cue Biopharma (NASDAQ:CUE) on Sunday shared topline results from a Phase 2 trial of CUE-221 in patients with moderate to severe chronic spontaneous urticaria. The study met its primary and secondary endpoints, demonstrating sustained efficacy and a favorable safety profile. Cue Biopharma shares init...
09-21 22:45
Cue Biopharma reports positive Phase 2 CUE-221 data
Cue Biopharma ( ($CUE) ) just unveiled an announcement. On September 20, 2026, ...
09-21 20:29
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83
B. Riley Securities analyst Mayank Mamtani initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces Price Target of $83.
09-18 18:39
Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(24.14) per share which missed the analyst consensus estimate of $(1.69) by 1328.4 percent. This is a 794.07 percent decrease over losses of $(2.70) per share from the same period last year. The company reported quarterly sales of $7.877 milli...
08-15 04:27
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Cue Biopharma reported second quarter 2026 financial results and business highlights, including the recent submission of an Investigational New Drug (IND) application for CUE-221 in food allergy applications, a $50 million private placement to support clinical development, and the appointment of new leadership. The company also announced Phase 2 data readouts for CUE-221 in Chronic Spontaneous Urticaria and plans to initiate a Phase 1 study for C...
08-14 20:05
Cue Biopharma Appoints James M. Ahlers CFO
Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer. Mr. Ahlers will report to President and Chief Executive Officer Shao-Lee Lin, ...
08-03 20:33
Cue Biopharma Announces $50 Million Private Placement
Cue Biopharma ( ($CUE) ) has issued an announcement. On July 9, 2026, Cue Bioph...
07-11 05:57
Cue Biopharma to raise $50M in oversubscribed private placement
Cue Biopharma (CUE) has entered into a definitive securities purchase agreement to raise approximately $50.0M in gross proceeds through a private placement with a group of accredited institutional inv...
07-10 16:08
